Recent scientific studies have indicated that an extract derived from the petals of the dahlia flower can effectively regulate blood glucose levels in individuals suffering from either prediabetes or type 2 diabetes. The extract functions by mitigating inflammation within the brain, thus enhancing the body’s capacity for blood sugar metabolism.
It has been ascertained that dahlia petal extract possesses the capability to maintain stable blood glucose levels.
A series of clinical trials spearheaded by the University of Otago have revealed that the extract from dahlia flower petals is conducive to stabilizing blood glucose levels in diabetic patients.
Supervised by Associate Professor Alexander Tups, an expert in neuroendocrinology at the Centre for Neuroendocrinology, the research team found that the reduction of brain inflammation—commonly aggravated by Western dietary habits—noticeably ameliorates the regulation of blood glucose levels.
Subsequent research led to the identification of an anti-inflammatory phytochemical that operates within the brain, thereby markedly improving the body’s blood sugar processing capabilities.
Associate Professor Tups elaborated, “We ascertained that the dahlia plant can be cultivated as a source for this specific phytochemical. Additionally, we identified two more plant-based molecules that augment the efficacy of the original molecule. This combination was shown to effectively inhibit brain inflammation and enhance blood sugar regulation in preclinical trials.”
Approximately one-quarter of the adult populace in Aotearoa is diagnosed with prediabetes, a condition characterized by marginally elevated blood glucose levels, indicating susceptibility to future development of type 2 diabetes. Absent any intervention, nearly 70 percent of these individuals will eventually develop type 2 diabetes.
In a rigorously controlled clinical trial involving participants diagnosed with prediabetes or type 2 diabetes, it was shown that the dahlia extract brought about substantial improvements in blood glucose regulation.
In preclinical trials involving animals, the research team successfully reversed brain inflammation, increased brain insulin sensitivity, and optimized blood sugar regulation.
Initiated with a grant in 2015 and in collaboration with Plant and Food Research, Associate Professor Tups regards the project as a pinnacle in his career.
“The discovery of three efficacious compounds naturally occurring in a flower that synergistically improve blood sugar regulation is quite monumental. Millions across the globe suffer from inadequate blood sugar management, and I genuinely believe our exhaustive research will provide much-needed relief,” he stated.
The research findings have been patented, and the team, in collaboration with Otago Innovation Limited (OIL) and other external partners, is in the process of introducing a natural supplement containing dahlia extract to the market. The aim is to support the maintenance of normal blood glucose and insulin levels.
Dr. Graham Strong, the project lead at OIL, stated that the collaboration amalgamates a diverse range of expertise and perspectives, culminating in an innovative, science-backed nutraceutical product. “The supplement offers a unique blend of nutritional compounds that support normal blood sugar and insulin levels. Clinical evidence confirms its utility for individuals diagnosed with prediabetes or type 2 diabetes to halt the progression of the condition,” he noted.
Reference: “Anti-diabetic Properties of Dahlia Flower Extract Evident through Enhanced Brain Insulin Function” by Dominik Pretz, Philip M Heyward, Jeremy Krebs, Joel Gruchot, Charles Barter, Pat Silcock, Nerida Downes, Mohammed Zubair Rizwan, Alisa Boucsein, Julia Bender, Elaine J Burgess, Geke Aline Boer, Pramuk Keerthisinghe, Nigel B Perry, and Alexander Tups, published on 18 June 2023 in Life Metabolism.
DOI: 10.1093/lifemeta/load026
